A crossover trial involving 12 T2DM patients with obesity with different interventions including ARNIs alone or ARNIs plus DPP4 inhibitors showed that ARNIs increase postprandial blood glucose by 57% with increasing levels of glucagon, C‐peptide, and GLP‐1 without effect on GIP and insulin levels.15 The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.